Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Benign Prostatic Hypertrophy Clear all
Recruiting No phase listed Observational

Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

NCT07016620
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Transperineal Laser Ablation (TPLA)
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 7:35 PM EDT
Active, not recruiting Not applicable Interventional

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

NCT05400980
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Urocross implant, Sham-control
Device · Diagnostic Test
Lead sponsor
Prodeon Medical, Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Maywood, Illinois • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Jul 21, 2026, 7:35 PM EDT
Terminated Not applicable Interventional Results available

Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia

NCT04398966
View directory record Official record
Conditions
BPH, Enlarged Prostate (BPH), Prostatic Hyperplasia
Interventions
Prostatic Artery Embolization (HydroPearl® compressible microspheres)
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 21, 2026, 7:35 PM EDT
Not listed Not applicable Interventional

Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)

NCT00274417
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
dutasteride
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
50 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Norfolk, Virginia • Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 2 Interventional

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 21, 2026, 7:35 PM EDT
Recruiting No phase listed Observational

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929
View directory record Official record
Conditions
Benign Prostatic Hypertrophy (BPH), Lower Urinary Track Symptoms
Interventions
Survey using a questionnaire.
Other
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Not applicable Interventional Results available

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II

NCT03123250
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Aquablation
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Not applicable Interventional

Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP

NCT05308017
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Richard Wolf 24F Laser scope, Karl Storz 28F Laser Scope
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

NCT02637960
View directory record Official record
Conditions
Nocturia
Interventions
Fedovapagon 2 mg, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Lincoln, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Jul 21, 2026, 7:35 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing UroLift Experience Against Rezūm

NCT04338776
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift, Rezum
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Royal Oak, Michigan • Garden City, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 21, 2026, 7:35 PM EDT
Recruiting No phase listed Observational

Customized TULSA-PRO Ablation Registry

NCT05001477
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Interventions
TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2061
U.S. locations
5
States / cities
West Hills, California • Jacksonville, Florida • York, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Early Phase 1 Interventional

Ultrasound-Guided Photoselective Vaporization of the Prostate

NCT02346500
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Transrectal Ultrasound
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 2 Interventional

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

NCT01939184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
WC3055, Placebo
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years and older · Male only
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
95
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 21, 2026, 7:35 PM EDT
Withdrawn Not applicable Interventional

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT04563221
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Prostatic artery embolization
Device
Lead sponsor
Andrew Picel
Other
Eligibility
45 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

NCT00645034
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
placebo, sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
35 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Laguna Woods, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Tadalafil, Placebo, Finasteride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Davis, California • Fresno, California • Laguna Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Jul 21, 2026, 7:35 PM EDT
Withdrawn Not applicable Interventional

Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men

NCT03043222
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Urinary Frequency/Urgency, Urinary Incontinence, Urge, Incontinence, Urinary, Nocturia
Interventions
UroLift as artifical device for prostatic urethral lift., Embospheres Microspheres as embolic agents for prostate artery embolization
Device
Lead sponsor
St. Louis University
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 4 Interventional Results available

Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

NCT05082142
View directory record Official record
Conditions
Kidney Calculi, Urologic Diseases, Benign Prostatic Hypertrophy
Interventions
Tranexamic acid
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

NCT01846793
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Laguna Beach, California • San Diego, California • Aventura, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Jul 21, 2026, 7:35 PM EDT
Terminated Phase 2 Interventional

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

NCT00743184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Interventions
ozarelix, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
50 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Therapy of Prostatic Symptoms

NCT00021814
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions
Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
3,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

NCT00609596
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
GI198745
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 21, 2026, 7:35 PM EDT
Not yet recruiting No phase listed Observational

The FLOW Registry.

NCT07430423
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 7:35 PM EDT
Completed Not applicable Interventional Results available

The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects

NCT00710749
View directory record Official record
Conditions
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
Interventions
Disposable device, Digital device, Clinic flow measurement
Device
Lead sponsor
Wellspect HealthCare
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Jul 21, 2026, 7:35 PM EDT